Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer - Denkert, C; Lambertini, C; Fasching, P A (J Clin Oncol, 2020)
et al.